DGIdb - PIMASERTIB Drug Record

PIMASERTIB chembl:CHEMBL2107832 Antineoplastic

Alternate Names:

PIMASERTIB
EMD-1036239
AS703026
MSC-1936369B
AS-703026
EMD 1036239
AS 703026
G-02443714
MSC1936369A
MSC1936369A; AS703026; EMD 1036239
MSC-1936369A

Drug Info:

Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.

PIMASERTIB MAP2K2

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Notes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions
PIMASERTIB MAP2K1

Interaction Score: 0.47

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions
PIMASERTIB NF1

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
PIMASERTIB NRAS

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus + Pimasertib

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
23629727

Sources:
JAX-CKB
PIMASERTIB BRAF

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Sorafenib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23629727

Sources:
ClearityFoundationBiomarkers JAX-CKB
PIMASERTIB KRAS

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
23629727 26228206

Sources:
ClearityFoundationBiomarkers JAX-CKB
PIMASERTIB PIK3CA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus + Pimasertib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23629727

Sources:
JAX-CKB
PIMASERTIB EGFR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + BEZ235

Approval Status Preclinical - Cell line xenograft

combination therapy Pimasertib + Sorafenib

PMIDs:
23629727

Sources:
JAX-CKB
PIMASERTIB TP53

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
26228206

Sources:
JAX-CKB

MyCancerGenome: PIMASERTIB
- Version: 20-Jun-2017
Alternate Names:

MSC1936369B Development Name

PIMASERTIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

JAX-CKB: Pimasertib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer

Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.

TALC: PIMASERTIB
- Version: 12-May-2016
Alternate Names:

PIMASERTIB Primary Drug Name

PIMASERTIB Drug Generic Name

MSC1936369B Drug Synonym

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2107832
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: PIMASERTIB
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2107832
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: PIMASERTIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Notes

combination therapy	Everolimus + Pimasertib
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

combination therapy	Pimasertib + Sorafenib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	Pimasertib + Gemcitabine
Indication/Tumor Type	pancreatic cancer
Response Type	sensitive

combination therapy	Pimasertib + BEZ235
Approval Status	Preclinical - Cell line xenograft
combination therapy	Pimasertib + Sorafenib

PIMASERTIB	Primary Drug Name
PIMASERTIB	Drug Generic Name
MSC1936369B	Drug Synonym

PIMASERTIB Drug Record

PIMASERTIB chembl:CHEMBL2107832 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Notes

PMIDs: None found

Sources: ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus + Pimasertib Indication/Tumor Type non-small cell lung carcinoma Response Type sensitive

PMIDs: 23629727

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Pimasertib + Sorafenib Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 23629727

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Pimasertib + Gemcitabine Indication/Tumor Type pancreatic cancer Response Type sensitive

PMIDs: 23629727 26228206

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus + Pimasertib Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 23629727

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Pimasertib + BEZ235 Approval Status Preclinical - Cell line xenograft combination therapy Pimasertib + Sorafenib

PMIDs: 23629727

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Pimasertib + Gemcitabine Indication/Tumor Type pancreatic cancer Response Type sensitive

PMIDs: 26228206

Sources: JAX-CKB

MyCancerGenome: PIMASERTIB

Alternate Names: MSC1936369B Development Name PIMASERTIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

JAX-CKB: Pimasertib

Alternate Names:

Drug Info:

TALC: PIMASERTIB

Alternate Names: PIMASERTIB Primary Drug Name PIMASERTIB Drug Generic Name MSC1936369B Drug Synonym

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2107832

Alternate Names:

Drug Info:

Publications:

ClearityFoundationBiomarkers: PIMASERTIB

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL2107832

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: PIMASERTIB

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Notes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus + Pimasertib

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
23629727

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Sorafenib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23629727

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
23629727 26228206

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus + Pimasertib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23629727

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + BEZ235

Approval Status Preclinical - Cell line xenograft

combination therapy Pimasertib + Sorafenib

PMIDs:
23629727

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Gemcitabine

Indication/Tumor Type pancreatic cancer

Response Type sensitive

PMIDs:
26228206

Sources:
JAX-CKB

Alternate Names:

MSC1936369B Development Name

PIMASERTIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

PIMASERTIB Primary Drug Name

PIMASERTIB Drug Generic Name

MSC1936369B Drug Synonym